View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Novartis AG: Annual update

Our credit view of this issuer reflects its wide geographical diversification, offset by its largest-selling drug and a degree of event risk.

Novartis AG - September 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Novartis AG - June 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Novartis AG - March 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Novartis AG: Key facts and statistics - 2023

A summary company profile, detailing Novartis’s business operations and financial highlights.

Novartis AG: Update to credit analysis

Our credit view of Novartis reflects its leading positions in pharmaceuticals and its strong pipeline, with growing exposure to patent expiries and some event risk.

Novartis AG - June 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Novartis AG - March 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Novartis AG: Key facts and statistics - 2022

A summary company profile, detailing Novartis AG’s business operations and financial highlights.

Novartis AG: Update following affirmation at A1, outlook changed to po...

Our credit view of Novartis AG reflects its leading positions in pharmaceuticals and its strong pipeline, with increasing exposure to patent expiries and some event risk.

Novartis AG: Update to credit analysis

Our credit view of Novartis AG reflects its leading positions in pharmaceuticals and strong pipeline, with some exposure to patent expiries and event risk.

Novartis AG - September 2022 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Novartis AG: Sandoz spin-off will reduce Novartis' business diversity;...

Novartis' separation of its Sandoz business through a 100% spin-off will leave it focused on innovative medicines.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Signs of Disinflation? A bear market bounce is underway after the S&P 500, Nasdaq 100 (QQQ), and Russell 2000 (IWM) found support at their respective downtrend channels, a possibility we discussed last week. Still, until the S&P 500, QQQ, and IWM can break above their various downtrends, we remain bearish, and believe investors should be using rallies to reduce overall exposure. Signs of Disinflation? We are starting to see early signs that inflation is peaking, as commodity prices have pulled...

Novartis AG - March 2022 (LTM)): Peer Snapshot

Compares key performance metrics against industry peers

Novartis AG: Update to credit analysis

Our credit view of Novartis AG reflects its leading positions in pharmaceuticals and strong pipeline, with some exposure to patent expiries and event risk.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

10-Year Treasury Yield Testing 40-Year Resistance; Upgrading Health Care to Overweight Whether or not the lows for this correction have already been established remains to be seen, but evidence is mounting that suggests a test of the lows, and possibly a break to new lows, is increasingly likely. Regardless, continue to stick with the commodity and defensive Sectors, all of which hit new price and RS highs in recent days. 10-Year Treasury Yield. We have discussed our expectations for rising ra...

Novartis AG - December 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

Moody's says Novartis' announced share buybacks do not materially affe...

Announcement: Moody's says Novartis' announced share buybacks do not materially affect its credit profile. Global Credit Research- 16 Dec 2021. Paris, December 16, 2021-- Moody's Investors Service informs today that Novartis AG's share buybacks, funded with recent sale proceeds, do not materially affect its credit profile.

Novartis AG - September 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch